Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 3/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | CKS1B | P61024 | 1/20 | 0.36 |
| ▸ | SKP1 | P63208 | 1/20 | 0.36 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.36 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6491658 | 0.75 | MEN1 (0.61) | MEN1KMT2AGAAMAPTNPSR1 | |
| SCHEMBL6494079 | 0.75 | MEN1 (0.61) | MEN1KMT2AGAAMAPTNPSR1 | |
| SCHEMBL6500581 | 0.75 | MEN1 (0.61) | MEN1KMT2AGAAMAPTNPSR1 | |
| SCHEMBL938796 | 0.74 | TDP1 (0.40) | MEN1KMT2AGAANPSR1TDP1 | |
| SCHEMBL25943020 | 0.73 | AKT1 (0.46) | CTSKCTSSCKS1BSKP1SKP2 | |
| SCHEMBL25496781 | 0.72 | MEN1 (0.56) | MEN1KMT2AGAAMAPTNPSR1 | |
| SCHEMBL25943024 | 0.72 | TDP1 (0.44) | MEN1KMT2AGAANPSR1ALDH1A1 | |
| SCHEMBL938794 | 0.71 | CTSK (0.33) | CTSKCTSSGPR88 | |
| SCHEMBL2334375 | 0.71 | CA1 (0.48) | TDP1 | |
| SCHEMBL7344378 | 0.71 | MEN1 (0.62) | MEN1KMT2AGAAMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875619-B2 | N-[4-(4-{2-[bis-((2S,3R)-2,3,4-trihydroxybutyl)amino]ethylamino}phenyl)butyl]-N'-(3,5-diamino-6-chloropyrazine-2-carbonyl)guanidine trihydrochloride; treating chronic bronchitis, cystic fibrosis, ventilator-induced pneumonia, asthma, chronic obstructive pulmonary disease, pneumonia and emphysema | PARION SCIENCES, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20060142581-A1 | Hetero substitued sodium channel blockers | PARION SCIENCES, INC. (US) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142581-A1 | Hetero substitued sodium channel blockers | SCN2B, CACNA1B, CACNA1G | MEN1 2258/4885KMT2A 1747/4885GAA 3638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.